Methylene Blue 5 mg – 60 κάψουλες

Κυανό του μεθυλενίου 5 mg — 60 ερευνητικές κάψουλες φαρμακευτικής ποιότητας. Methylene blue holds a unique position in the history of pharmacology: it was the first synthetic drug ever used in humans (Ehrlich, 1891), the founding lead compound of every phenothiazine antipsychotic, the parent scaffold of every methylene-bridged tau aggregation inhibitor, και the gold-stκαιard antidote for methemoglobinemia. In neuroscience, it has emerged over the past two decades as the most extensively characterized low-dose mitochondrial enhancer, with controlled human imaging studies demonstrating measurable effects on brain glucose metabolism, BOLD response και functional memory at doses an order of magnitude below the antimethemoglobinemia range. The 5 mg per-capsule format corresponds precisely to the low-dose nootropic και mitochondrial-enhancement window characterized in published clinical pharmacology.

Επισκόπηση έρευνας

Methylene blue (methylthioninium chloride) is a phenothiazine dye with an extraordinary range of well-characterized pharmacology, dose-dependent και frequently U-shaped [1]. At low concentrations (≤ 1 mg/kg), it acts as an alternative electron carrier in the mitochondrial electron transport chain — accepting electrons from NADH και donating them directly to cytochrome c — bypassing complex I/III blockades και increasing cellular ATP production και oxygen consumption rate [1,2]. At slightly higher concentrations it inhibits monoamine oxidase και tau aggregation, και at clinical-antidote concentrations it reduces methemoglobin to hemoglobin via the NADPH-dependent diaphorase pathway. Functional human imaging at 0.5–4 mg/kg shows increased cerebral glucose metabolism, BOLD response in memory-related circuits, και improved performance on declarative-memory tasks [3]. The molecule has a > 130-year clinical safety history, with the principal contraindications well-mapped (G6PD deficiency; concurrent serotonergic agents).

Κύριοι τομείς έρευνας

• Μιτοχονδριακή βιοενεργητική και electron-transport bypass — the canonical small molecule for studying alternative-electron-carrier pharmacology και rescue of complex-I-deficient phenotypes [1,2].
• Cognitive και memory research — controlled human fMRI/PET studies show enhanced memory-task performance και increased brain glucose metabolism at low-dose ranges [3].
• Tauopathy και neurodegeneration — the parent scaffold for hydromethylthionine και a workhorse tool in tau-aggregation assays; investigated in AD, FTD και PSP models [1].
• Mood και psychiatric research — studied in bipolar depression και major depressive disorder, leveraging dose-dependent MAO-A inhibition και mitochondrial enhancement [1].
• Methemoglobinemia και oxidative-redox research — the gold-stκαιard antidote και a robust probe of NADPH-diaphorase activity, G6PD-deficiency phenotypes και free-radical biology [1].

Βιβλιογραφία

1. Tucker D, Lu Y, Zhang Q. From mitochondrial function to neuroprotection — an emerging role for methylene blue. Mol Neurobiol. 2018;55(6):5137–5153.
2. Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence και enhances key mitochondrial biochemical pathways. FASEB J. 2008;22(3):703–712.
3. Rodriguez P, Zhou W, Barrett DW, et al. Multimodal rκαιomized functional MR imaging of the effects of methylene blue in the human brain. Radiology. 2016;281(2):516–526.